The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck

Sponsor
Royal Marsden NHS Foundation Trust (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05808920
Collaborator
(none)
400
36

Study Details

Study Description

Brief Summary

The RESCUE study is a combined retrospective and prospective multicentre cohort study investigating the survival and functional outcomes in patients undergoing salvage surgery for recurrent, residual, and new primary head and neck squamous cell carcinoma (SCC).

Additionally, the RESCUE study will contain an exploratory molecular analysis of consenting patients to assess the relationship between cancer genomics, previous radiotherapy, and recurrence in head and neck cancer.

Condition or Disease Intervention/Treatment Phase
  • Genetic: Molecular Analyses

Detailed Description

The RESCUE study is a combined retrospective and prospective multicentre cohort study investigating the survival and functional outcomes in patients undergoing salvage surgery for recurrent, residual, and new primary head and neck squamous cell carcinoma (SCC).

Additionally, the RESCUE study will contain an exploratory molecular analysis of consenting patients to assess the relationship between cancer genomics, previous radiotherapy, and recurrence in head and neck cancer.

The aim of this study is to determine the survival, functional and quality of life outcomes of patients undergoing all salvage surgery for recurrent, residual and new primary head and neck SCC, and to establish the genetic architecture and clonal evolution H&N SCC after previous treatment for radiotherapy cancer.

Study Design

Study Type:
Observational
Anticipated Enrollment :
400 participants
Observational Model:
Cohort
Time Perspective:
Other
Official Title:
The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck
Anticipated Study Start Date :
Apr 1, 2023
Anticipated Primary Completion Date :
Apr 1, 2026
Anticipated Study Completion Date :
Apr 1, 2026

Arms and Interventions

Arm Intervention/Treatment
Group 1

Participants with previous diagnosis of H&N SCC treated with radiotherapy. Recurrent, residual, or new primary SCC of the oropharynx, oral cavity, larynx, and hypopharynx treated with salvage surgery

Genetic: Molecular Analyses
Nucleic acid extraction, protein analysis. Tumour tissue, blood and saliva samples collected.

Outcome Measures

Primary Outcome Measures

  1. Ascertain the 2-year disease-free survival post salvage surgery [Study duration is 3 years to include 1 year recruitment period. Active follow-up for patients is up to 2 years.]

    Ascertain the 2-year disease-free survival post salvage surgery for recurrent/ residual/ new primary head and neck SCC (split cohort of prospective and retrospective patients)

Secondary Outcome Measures

  1. Define the 2- and 5-year overall and disease specific survival in retrospectively identified patients [Study duration is 3 years to include 1 year recruitment period. Active follow-up for prospective patients is up to 2 years. Follow-up for retrospective patients is up to 5 years.]

    Define the 2- and 5-year overall and disease specific survival in retrospectively identified patients undergoing salvage surgery for recurrent/ residual/ new primary head and neck SCC

  2. Define the 2 year overall and disease specific survival in prospectively identified patients [Study duration is 3 years to include 1 year recruitment period. Active follow-up for patients is up to 2 years.]

    Define the 2 year overall and disease specific survival in prospectively identified patients undergoing salvage surgery for recurrent/ residual/ new primary head and neck SCC

  3. Report on gross functional outcomes by documenting rates of gastrostomy and tracheostomy dependence at 1-year post-salvage surgery. [Study duration is 3 years with up to 2 years follow-up in prospective and up to 5 years follow-up in retrospective patients. Functional outcomes will be measured from the date of surgery.]

    Report on gross functional outcomes by documenting rates of gastrostomy and tracheostomy dependence at 1-year post-salvage surgery.

  4. For the prospective cohort assess the overall quality-of-life outcomes pre-operatively and at 6- and 12-months post-surgery using validated questionnaires. [University of Washing Quality of life questionnaire distributed pre-operatively, 6 months and 12 months.]

    For the prospective cohort assess the overall quality-of-life outcomes at pre-operatively and at 6- and 12-months post-surgery using validated University of Washington Quality of Life questionnaire.

  5. For the prospective cohort assess the swallow-related quality-of-life outcomes at pre-operatively and at 6- and 12-months post-surgery using validated questionnaires. [MD Anderson Dysphagia Inventory distributed pre-operatively, 6 months and 12 months.]

    For the prospective cohort assess the swallow-related quality-of-life outcomes pre-operatively and at 6- and 12-months post-surgery using validated questionnaires.

  6. Estimate the rates of close and involved surgical margins across all surgical salvage procedures [Through study completion, expected duration of 3 years]

    Estimate the rates of close and involved surgical margins across all surgical salvage procedures

  7. Determine the impact of close and involved margins on overall survival outcomes [Through study completion, expected duration of 3 years]

    Determine the impact of close and involved margins on overall survival outcomes

  8. Determine the impact of close and involved margins on disease-free survival outcomes [Through study completion, expected duration of 3 years]

    Determine the impact of close and involved margins on disease-free survival outcomes

  9. Determine the impact of close and involved margins on disease-specific survival outcomes [Through study completion, expected duration of 3 years]

    Determine the impact of close and involved margins on disease-specific survival outcomes

  10. Establish the rates of super-selective, selective and modified/ radical salvage neck dissection in clinically N0 and N+ necks [Through study completion, expected duration of 3 years]

    Establish the rates of super-selective, selective and modified/ radical salvage neck dissection in clinically N0 and N+ necks

  11. Ascertain how the extent of salvage neck dissection influences overall survival outcomes. [Through study completion, expected duration of 3 years]

    Ascertain how the extent of salvage neck dissection influences overall survival outcomes.

  12. Ascertain how the extent of salvage neck dissection influences disease-free survival outcomes. [Through study completion, expected duration of 3 years]

    Ascertain how the extent of salvage neck dissection influences disease-free survival outcomes.

  13. Ascertain how the extent of salvage neck dissection influences disease-specific survival outcomes. [Through study completion, expected duration of 3 years]

    Ascertain how the extent of salvage neck dissection influences disease-specific survival outcomes.

  14. Estimate the rate of occult nodal metastasis in clinically N0 necks with locally recurrent disease [Through study completion, expected duration of 3 years]

    Estimate the rate of occult nodal metastasis in clinically N0 necks with locally recurrent disease

  15. Describe the impact of neck dissection on overall survival outcomes in patients with clinically N0 necks with and without subsequent occult nodal disease [Through study completion, expected duration of 3 years]

    Describe the impact of neck dissection on overall survival outcomes in patients with clinically N0 necks with and without subsequent occult nodal disease

  16. Describe the impact of neck dissection on disease-free survival outcomes in patients with clinically N0 necks with and without subsequent occult nodal disease [Through study completion, expected duration of 3 years]

    Describe the impact of neck dissection on disease-free survival outcomes in patients with clinically N0 necks with and without subsequent occult nodal disease

  17. Describe the impact of neck dissection on disease-specific survival outcomes in patients with clinically N0 necks with and without subsequent occult nodal disease [Through study completion, expected duration of 3 years]

    Describe the impact of neck dissection on disease-specific survival outcomes in patients with clinically N0 necks with and without subsequent occult nodal disease

  18. Using multi-variate analysis, establish the clinical prognostic indicators of overall, disease free and disease specific survival. [Through study completion, expected duration of 3 years]

    Establish the clinical prognostic indicators of positive survival and functional outcomes

  19. Using multi-variate analysis, establish the clinical prognostic indicators 12 month tracheostomy and gastrostomy dependence. [Through study completion, expected duration of 3 years]

    Establish the clinical prognostic indicators of functional outcomes

  20. Compare the DNA genetic and epigenetic changes in residual, recurrent, and new primary head and neck squamous cell carcinoma with primary tumour and germline DNA samples. [Through study completion, expected duration of 3 years]

    Assess the molecular makeup of head and neck tumours that have not responded to radiotherapy treatment, or which recur having previously responded.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Aged over 18

  2. Previous H&N SCC treated with radiotherapy with or without chemotherapy

  3. Local or regionally recurrent, residual, or new primary SCC of the oropharynx, oral cavity, larynx, and hypopharynx

  4. Ability to give informed consent for biological sample collection (molecular analysis study only)

Exclusion Criteria:
  1. Nasopharyngeal and cutaneous SCC of the H&N

  2. Thyroid, salivary gland, and non-squamous cell H&N cancers

  3. Presence of distant metastasis (M1) or surgically inoperable T4b tumours

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Royal Marsden NHS Foundation Trust

Investigators

  • Principal Investigator: Vinidh Paleri, Royal Marsden Hospital NHS Foundation Trust

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Royal Marsden NHS Foundation Trust
ClinicalTrials.gov Identifier:
NCT05808920
Other Study ID Numbers:
  • CCR 5752
First Posted:
Apr 12, 2023
Last Update Posted:
Apr 12, 2023
Last Verified:
Mar 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 12, 2023